FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163854220> ?p ?o ?g. }

• W3163854220 endingPage "3482" @default.
• W3163854220 startingPage "3465" @default.
• W3163854220 abstract "Patients with congenital vascular malformations often suffer from an impaired quality of life (QoL) because of pain and functional disabilities. Previous studies have shown that the mTOR inhibitor sirolimus can reduce complaints and improve QoL in some patients. High target levels of sirolimus of 10–15 ng/ml were well tolerated; however, in a relative high percentage of patients sirolimus caused serious adverse events (AEs). A case series of 12 patients with therapy-resistant low-flow vascular malformations was treated with sirolimus, using low target levels of 4–10 ng/ml. Efficacy of sirolimus was evaluated in regard to pain symptoms using the visual analogue scale/numeric rating scale and patients reported QoL. To rule out a placebo effect of sirolimus, sirolimus was stopped after a certain time point and reintroduced as soon as complaints returned. Adverse events were closely monitored and graded using the Common Terminology Criteria for Adverse Events (CTCAE) grading. An improvement in symptoms was seen in 92% (n = 11/12) of patients. In nine patients pain complaints returned. Seven out of nine of them (78%) again experienced a reduction of symptoms after restarting sirolimus treatment. Despite low target levels, these response rates are comparable to those found in the literature using higher target levels of sirolimus. However, significantly less serious AEs were observed with low dose sirolimus, suggesting low dose sirolimus might be safer. Unfortunately, young adolescent female patients developed serious menstrual disturbances during treatment with low dose sirolimus. We describe this adverse event for the first time in patients with congenital vascular malformations and this might be specifically related to low dose sirolimus. Low dose sirolimus showed a high efficacy in patients with therapy-resistant and low-flow malformation, with a lower incidence of serious adverse events. At the same time a new adverse event, namely menstrual cycle disturbance, was observed in young adolescents, indicating the need for caution when sirolimus is given. This is extremely relevant to patients with low-flow vascular malformation, who are likely to require lifelong treatment for their condition." @default.
• W3163854220 created "2021-05-24" @default.
• W3163854220 creator A5010417540 @default.
• W3163854220 creator A5017029863 @default.
• W3163854220 creator A5027568558 @default.
• W3163854220 creator A5034404496 @default.
• W3163854220 creator A5037151292 @default.
• W3163854220 creator A5038310290 @default.
• W3163854220 creator A5047719160 @default.
• W3163854220 creator A5062201991 @default.
• W3163854220 creator A5066765820 @default.
• W3163854220 date "2021-05-18" @default.
• W3163854220 modified "2023-10-11" @default.
• W3163854220 title "Patients with Congenital Low-Flow Vascular Malformation Treated with Low Dose Sirolimus" @default.
• W3163854220 cites W1706136667 @default.
• W3163854220 cites W1969510397 @default.
• W3163854220 cites W1983143758 @default.
• W3163854220 cites W1987378904 @default.
• W3163854220 cites W1995976732 @default.
• W3163854220 cites W2000239178 @default.
• W3163854220 cites W2000566468 @default.
• W3163854220 cites W2012945996 @default.
• W3163854220 cites W2022005587 @default.
• W3163854220 cites W2041472888 @default.
• W3163854220 cites W2059349437 @default.
• W3163854220 cites W2060826753 @default.
• W3163854220 cites W2064380726 @default.
• W3163854220 cites W2064867593 @default.
• W3163854220 cites W2080100938 @default.
• W3163854220 cites W2140212510 @default.
• W3163854220 cites W2143112776 @default.
• W3163854220 cites W2165555140 @default.
• W3163854220 cites W2282181553 @default.
• W3163854220 cites W2331643287 @default.
• W3163854220 cites W2392938395 @default.
• W3163854220 cites W2553676809 @default.
• W3163854220 cites W2588595914 @default.
• W3163854220 cites W2625755866 @default.
• W3163854220 cites W2762248825 @default.
• W3163854220 cites W2774637416 @default.
• W3163854220 cites W2892878289 @default.
• W3163854220 cites W2898708409 @default.
• W3163854220 cites W2912947723 @default.
• W3163854220 cites W2913989733 @default.
• W3163854220 cites W3126380139 @default.
• W3163854220 cites W625451847 @default.
• W3163854220 doi "https://doi.org/10.1007/s12325-021-01758-y" @default.
• W3163854220 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8190005" @default.
• W3163854220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34003452" @default.
• W3163854220 hasPublicationYear "2021" @default.
• W3163854220 type Work @default.
• W3163854220 sameAs 3163854220 @default.
• W3163854220 citedByCount "13" @default.
• W3163854220 countsByYear W31638542202021 @default.
• W3163854220 countsByYear W31638542202022 @default.
• W3163854220 countsByYear W31638542202023 @default.
• W3163854220 crossrefType "journal-article" @default.
• W3163854220 hasAuthorship W3163854220A5010417540 @default.
• W3163854220 hasAuthorship W3163854220A5017029863 @default.
• W3163854220 hasAuthorship W3163854220A5027568558 @default.
• W3163854220 hasAuthorship W3163854220A5034404496 @default.
• W3163854220 hasAuthorship W3163854220A5037151292 @default.
• W3163854220 hasAuthorship W3163854220A5038310290 @default.
• W3163854220 hasAuthorship W3163854220A5047719160 @default.
• W3163854220 hasAuthorship W3163854220A5062201991 @default.
• W3163854220 hasAuthorship W3163854220A5066765820 @default.
• W3163854220 hasBestOaLocation W31638542201 @default.
• W3163854220 hasConcept C126322002 @default.
• W3163854220 hasConcept C197934379 @default.
• W3163854220 hasConcept C2777793932 @default.
• W3163854220 hasConcept C2777921159 @default.
• W3163854220 hasConcept C2779699572 @default.
• W3163854220 hasConcept C42219234 @default.
• W3163854220 hasConcept C71924100 @default.
• W3163854220 hasConceptScore W3163854220C126322002 @default.
• W3163854220 hasConceptScore W3163854220C197934379 @default.
• W3163854220 hasConceptScore W3163854220C2777793932 @default.
• W3163854220 hasConceptScore W3163854220C2777921159 @default.
• W3163854220 hasConceptScore W3163854220C2779699572 @default.
• W3163854220 hasConceptScore W3163854220C42219234 @default.
• W3163854220 hasConceptScore W3163854220C71924100 @default.
• W3163854220 hasIssue "6" @default.
• W3163854220 hasLocation W31638542201 @default.
• W3163854220 hasLocation W31638542202 @default.
• W3163854220 hasLocation W31638542203 @default.
• W3163854220 hasLocation W31638542204 @default.
• W3163854220 hasOpenAccess W3163854220 @default.
• W3163854220 hasPrimaryLocation W31638542201 @default.
• W3163854220 hasRelatedWork W118413278 @default.
• W3163854220 hasRelatedWork W2090554093 @default.
• W3163854220 hasRelatedWork W2582100283 @default.
• W3163854220 hasRelatedWork W2883207564 @default.
• W3163854220 hasRelatedWork W2911924327 @default.
• W3163854220 hasRelatedWork W3033069928 @default.
• W3163854220 hasRelatedWork W3180418360 @default.
• W3163854220 hasRelatedWork W4297889242 @default.
• W3163854220 hasRelatedWork W4385898055 @default.
• W3163854220 hasRelatedWork W4386398816 @default.

• next